Immunic, Inc. (IMUX) stock
Close on Nov 11, 2026Market cap $110.79MP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $110.79M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.87
- Dividend yield
- 0.00%
- Free cash flow yield
- -79.47%
Fundamentals
- Net income
- -$111.57M
- EPS, diluted
- -$4.17
- Free cash flow
- -$88.05M
- Book value per share
- $3.00
- Diluted shares
- 43M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $8.04
- Open
- $8.20
- Day's range
- $8.08 – $8.42
- Volume
- 157,210
- Average volume (20 days)
- 287,235
- Beta (5 years)
- 1.04
- 52-week range
- $5.06 – $17.43
- RSI (14 days)
- 50.6
- Volatility (1 year)
- 81.8%
- Relative volume
- 0.54×
- WACC
- 10.1%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMUX | S&P 500 | Difference | IMUX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.9% | -2.4% | +1.6 pts | ||
| 3 months | -47.5% | -1.2% | −46.4 pts | ||
| Year to date | +52.1% | +12.3% | +39.9 pts | ||
| 1 year | +4.1% | +12.4% | −8.3 pts | ||
| 3 years | -23.4% | +78.8% | −102.2 pts | -8.5% | +21.4% |
| 5 years | -91.9% | +75.2% | −167.1 pts | -39.5% | +11.9% |
| 10 years | -99.7% | +311.1% | −410.8 pts | -43.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immunic filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Update
- Update
About Immunic
Pharmaceutical Preparations
Immunic, Inc. is a clinical-stage biotechnology company focused on developing oral therapies for serious chronic inflammatory and autoimmune conditions, specifically targeting neurologic and gastrointestinal diseases. The company’s pipeline includes vidofludimus calcium, a small molecule candidate currently in Phase 3 clinical trials for relapsing multiple sclerosis. Its gastrointestinal program, IMU-856, targets epithelial regeneration and intestinal barrier restoration for disorders such as celiac disease and inflammatory bowel disease. Additionally, Immunic is advancing the preclinical IMU-381 program, which utilizes its Nurr1 platform for autoimmune indications. Immunic does not have commercial products, focusing its activities on clinical-stage patient populations with significant unmet medical needs.
Company profile, executives and historyImmunic stock: common questions
What is Immunic's stock price?
IMUX closed at $8.12 on Nov 11, 2026, up 1.00% on the day. Over the past 52 weeks it traded between $5.06 and $17.43.
What is Immunic's market cap?
Immunic was worth $110.79M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IMUX's P/E ratio?
Immunic lost money over the twelve months to Jun 30, 2026 (diluted EPS -$4.17), so it has no meaningful P/E ratio.
Does Immunic pay a dividend?
No. Immunic has not paid a cash dividend over the last twelve months.
When does Immunic report earnings next?
Immunic is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IMUX stock performed over the past year?
Including dividends, IMUX returned +4.1% over the past year, against +12.4% for the S&P 500.
Who are Immunic's competitors?
Companies most similar to Immunic by business, industry and size include EVMN, TLSA, ANNX, YARW, ZBIO.
See a number that looks wrong?